tbuckley/cabot-search huggingface dataset:
Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care
Authors: Christopher J Black, Orla Craig, David J Gracie, Alexander C Ford
Journal: Gut (2020)

Objectives Despite being proposed 4 years ago, there has been no independent validation study of the Rome IV criteria for IBS. We assessed their performance for the diagnosis of IBS in secondary care and compared them with the previous iteration, the Rome III criteria. Design We collected complete symptom data from consecutive adult patients with suspected IBS referred to a single UK clinic. All subjects underwent relatively standardised workup, with assessors blinded to symptom status. The reference standard used to confirm IBS was the presence of lower abdominal pain or discomfort in association with altered stool form or frequency, in a patient with no evidence of organic gastrointestinal disease after investigation. Sensitivity, specificity and positive and negative likelihood ratios (LRs), with 95% CIs, were calculated for each of the diagnostic criteria. Results The level of agreement between the Rome IV and Rome III criteria was good (kappa=0.65). Compared with the reference standard, sensitivity and specificity of the Rome IV criteria in 572 patients (431 (75.3%) women, mean age 36.5 years) were 82.4% and 82.9%, respectively. Positive and negative LRs for the Rome IV criteria were 4.82 (95% CI 3.30 to 7.28) and 0.21 (95% CI 0.17 to 0.26), respectively. The Rome IV criteria performed best in those with IBS with constipation or mixed bowel habits. In 471 patients (350 (74.3%) women, mean age 36.7 years), compared with the reference standard, the sensitivity and specificity of the Rome III criteria were 85.8% and 65.0%; positive and negative LRs were 2.45 (95% CI 1.90 to 3.27) and 0.22 (0.16 to 0.29), respectively. Incorporating mood and extraintestinal symptom reporting into diagnostic criteria did not improve their performance significantly. Conclusions The Rome IV criteria performed significantly better than the Rome III criteria in diagnosing IBS in this single centre secondary care study, although the clinical relevance of this is uncertain.
1605P Number of untimely deaths prevented with ALK-inhibitors in Brazilian patients with advanced non-small cell lung cancer with ALK driver mutations
Authors: R.A. Pellegrini, G. Lenz, B.D. Cruz, L.S. Lago, P.S. Azevedo, L.L. Tôrres, G. Lopes, J.A. Teodoro
Journal: Annals of Oncology (2020)
Drinking Water in the United States: Implications of Water Safety, Access, and Consumption
Authors: Anisha I. Patel, Christina E. Hecht, Angie Cradock, Marc A. Edwards, Lorrene D. Ritchie
Journal: Annual Review of Nutrition (2020)

Recent water quality crises in the United States, and recognition of the health importance of drinking water in lieu of sugar-sweetened beverages, have raised interest in water safety, access, and consumption. This review uses a socioecological lens to examine these topics across the life course. We review water intakes in the United States relative to requirements, including variation by age and race/ethnicity. We describe US regulations that seek to ensure that drinking water is safe to consume for most Americans and discuss strategies to reduce drinking water exposure to lead, a high-profile regulated drinking water contaminant. We discuss programs, policies, and environmental interventions that foster effective drinking water access, a concept that encompasses key elements needed to improve water intake. We conclude with recommendations for research, policies, regulations, and practices needed to ensure optimal water intake by all in the United States and elsewhere.
A single-cell survey of cellular hierarchy in acute myeloid leukemia
Authors: Junqing Wu, Yanyu Xiao, Jie Sun, Huiyu Sun, Haide Chen, Yuanyuan Zhu, Huarui Fu, Chengxuan Yu, Weigao E., Shujing Lai, Lifeng Ma, Jiaqi Li, Lijiang Fei, Mengmeng Jiang, Jingjing Wang, Fang Ye, Renying Wang, Ziming Zhou, Guodong Zhang, Tingyue Zhang, Qiong Ding, Zou Wang, Sheng Hao, Lizhen Liu, Weiyan Zheng, Jingsong He, Weijia Huang, Yungui Wang, Jin Xie, Tiefeng Li, Tao Cheng, Xiaoping Han, He Huang, Guoji Guo
Journal: Journal of Hematology & Oncology (2020)

Abstract Background Acute myeloid leukemia (AML) is a fatal hematopoietic malignancy and has a prognosis that varies with its genetic complexity. However, there has been no appropriate integrative analysis on the hierarchy of different AML subtypes. Methods Using Microwell-seq, a high-throughput single-cell mRNA sequencing platform, we analyzed the cellular hierarchy of bone marrow samples from 40 patients and 3 healthy donors. We also used single-cell single-molecule real-time (SMRT) sequencing to investigate the clonal heterogeneity of AML cells. Results From the integrative analysis of 191727 AML cells, we established a single-cell AML landscape and identified an AML progenitor cell cluster with novel AML markers. Patients with ribosomal protein high progenitor cells had a low remission rate. We deduced two types of AML with diverse clinical outcomes. We traced mitochondrial mutations in the AML landscape by combining Microwell-seq with SMRT sequencing. We propose the existence of a phenotypic “cancer attractor” that might help to define a common phenotype for AML progenitor cells. Finally, we explored the potential drug targets by making comparisons between the AML landscape and the Human Cell Landscape. Conclusions We identified a key AML progenitor cell cluster. A high ribosomal protein gene level indicates the poor prognosis. We deduced two types of AML and explored the potential drug targets. Our results suggest the existence of a cancer attractor.
357TiP SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Authors: J. Cortés, S. Diab, R.K. Basho, M. Oliveira, T. Pluard, C. Alemany, U. Brown-Glaberman, J. Meisel, V. Boni, R. Sinha, L. García Estevez, J. Ettl, S. Kuemmel, L.M. Manso Sanchez, Y.W. Moon, R. Villanueva Vazquez, R. Wuerstlein, Y. Wang, Z. Wang, H. Han
Journal: Annals of Oncology (2020)
120P Predictive biomarkers for hyper progression in response to immune checkpoint inhibitors therapy: Analysis of somatic alterations by NGS
Authors: I.R.R. Gonzalez Espinoza, N. Cortés Escobar, R. Ibarra Fernández, J.C. Garibay Díaz, S. Sánchez Sosa, A. Gozalishvili Boncheva, M. Sabaté Fernández, J.C. García Reyna, E. Acosta Ponce de León, A. Domínguez Peregrina, M.D.J. González Blanco, C. Aguilar Jímenez, G.I. Íñiguez López, F.D.J. Vizcarra Ramos, M. Lujano de los Santos, D. Arizpe Bravo, F.J. Ceja Utrera, E. Bringas Locela, L.R. Barragán Gárate, J.M. Aguilar Priego
Journal: Annals of Oncology (2020)
711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
Authors: L. Albiges, N. Tannir, M. Burotto, D.F. McDermott, E.R. Plimack, P. Barthélémy, C.G. Porta, T.B. Powles, F. Donskov, S. George, C. Kollmannsberger, H. Gurney, M-O. Grimm, Y. Tomita, D. Castellano Gauna, B.I. Rini, T.K. Choueiri, S.S. Saggi, M.B. McHenry, R.J. Motzer
Journal: Annals of Oncology (2020)
Complex biliary stricture treated by percutaneous single-operator cholangioscopy and multiple biodegradable stents
Authors: Enrique Pérez-Cuadrado-Robles, Guillaume Perrod, Hedi Benosman, Nadia Moussa, Olivier Pellerin, Christophe Cellier, Gabriel Rahmi
Journal: Endoscopy (2020)

The endoscopic treatment of biliopancreatic disease in patients with altered surgical anatomy is challenging [1]. A 42-year-old woman who had previously undergone a standard Whipple procedure surgery because of duodenal adenocarcinoma presented with multiple large biliary stones and a symptomatic benign stricture of the hepaticojejunal anastomosis, detected by magnetic resonance imaging. Double-balloon enteroscopy failed to reach the hepaticojejunal anastomosis and hybrid radiological/endoscopic treatment was decided upon.
1033P The phase I INSIGHT platform trial: Strata A and B evaluating feasibility of intratumoral and intraperitoneal IMP321 (soluble LAG-3 protein, eftilagimod alpha) in advanced solid tumours
Authors: S-E. Al-Batran, D.W. Müller, M-R. Rafiyan, D. Kiselicki, T. Habibzade, C. Brignone, R. Eickhoff, E. Jäger, T.O. Goetze
Journal: Annals of Oncology (2020)
1169P First-line fluoropyrimidine and oxaliplatin chemotherapy in gastro-entero-pancreatic grade 3 well-differentiated neuroendocrine tumours (NET G3)
Authors: G. Lamberti, S. Pusceddu, T. Ibrahim, A. Bongiovanni, R. Berardi, M. Torniai, N. Prinzi, L. Manuzzi, D. Campana
Journal: Annals of Oncology (2020)
1368P Lorlatinib in pretreated ALK/ROS1-positive non-small cell lung cancer (NSCLC): Results from the German early access program
Authors: N. Frost, P. Christopoulos, D. Kauffmann-Guerrero, J.A. Stratmann, R. Riedel, M. Schäfer, J. Alt, S. Guetz, J. Brinkmann, F. Griesinger
Journal: Annals of Oncology (2020)
949P Impact of antibiotic use and derived neutrophil to lymphocyte ratio (dNLR) in patients with recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC) treated with immunotherapy
Authors: M. Plana, G. Cefarelli, P. Guillén, A. Esteve, M. Oliva, A. Gonzalez, J. Brenes, N. Vilariño, E. Vilajosana, V. Gomez, R. Mesía, M. Taberna
Journal: Annals of Oncology (2020)
560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment
Authors: A.B. Azaro Pedrazzoli, V. Moreno, C.A. Gomez-Roca, C. Even, P. Cassier, T.C. Hernandez Guerrero, M. de Miguel, I. Korakis, D. Purcea, E. Roy, K. Gollmer, C. Riff, S.A. Szyldergemajn, E. Calvo
Journal: Annals of Oncology (2020)
1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study
Authors: J.F. Vansteenkiste, E.F. Smit, H.J.M. Groen, E.B. Garon, R.S. Heist, T. Hida, M. Nishio, K. Kokowski, C. Grohe, N. Reguart, A.S. Mansfield, A. Robeva, S. Ghebremariam, M. Waldron-Lynch, M. Akimov, N. Nwana, M. Giovannini, J. Wolf
Journal: Annals of Oncology (2020)
Skin-Colored Nodule on the Scalp of a Middle-aged Man
Authors: Geeti Khullar, Deepti Agarwal, Mithilesh Chandra
Journal: JAMA Dermatology (2020)

An otherwise healthy man in his 40s presents with an asymptomatic nodule on his scalp; examination revealed a skin-colored, firm, nontender nodule with overlying normal skin on the right occipital region. What is your diagnosis?
Chromosome Aberrations in Syrian Hamster Embryo Cells Transformed After Exposure to Ultraviolet-Irradiated Herpes Simplex Virus Type 1 or 2 2
Authors: Maurice Nachtigal, Ronald Duff, Fred Rapp
Journal: JNCI Journal of the National Cancer Institute (1975)

Six Syrian hamster embryo cell lines (14-012-8-1, KOS-6-1, 333-8-9, 333-2-29, MS-4-1, FR-6-1), developed after exposure of primary cultures to different strains of UV-irradiated herpes simplex virus (HSV) type 1 or 2, were analyzed for chromosome aberrations. All the cell lines showed chromosome stability (number of chromosomes were maintained within a narrow range of variation in the diploid region) and a low incidence of polyploids, endoreduplications, and metaphases with pulveration or extensively fragmented chromosomes. The cell lines, passaged over long periods of time in vitro, developed marker chromosomes that suggested a clonal-type evolution of the cell populations. Two cell lines, 333-8-9 and 14-012-8-1, showed two different marker chromosomes with large heterochromatic regions. Chromosomes with abnormal heterochromatic regions, which often appeared like prominent secondary constrictions, were found in all the cell lines we examined. The level of chromosome breakage was low in all the cell lines except the highly tumorigenic cell line 333-2-29, which had a high incidence of cells with single or double chromatinic bodies. The abnormal heterochromatic regions that occurred on marker chromosomes and prominent secondary constrictions were interpreted as a possible chromosomal effect of the HSV. The karyotypic stability and low incidence of open breaks might have been the result of UV irradiation of the HSV
1344P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on second-line or further line therapy: Real world data from the German CRISP registry
Authors: M. Falk, J. Roeper, L. Heukamp, M. Tiemann, A. Stenzinger, M. Thomas, P. Christopoulos, F. Griesinger
Journal: Annals of Oncology (2020)
88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer
Authors: M. Schmidt, I. Vogler, E. Derhovanessian, T. Omokoko, E. Godehardt, S. Attig, A. Cortini, S. Newrzela, J. Grützner, S. Bolte, D. Langer, M. Eichbaum, H. Lindman, S. Pascolo, A. Schneeweiss, T. Sjöblom, Ö. Türeci, U. Sahin
Journal: Annals of Oncology (2020)
715P Immune checkpoint therapy (ICT) re-challenge after immune-related adverse events (irAEs) in genitourinary cancers (GUC)
Authors: B. Siddiqui, J.S. Gheeya, R. Goswamy, S.K. Subudhi, J. Gao, M.T. Campbell, A.Y. Shah, P. Msaouel, A.J. Zurita-Saavedra, S. Goswami, J. Wang, E. Jonasch, A.O. Siefker-Radtke, P. Sharma, N. Tannir
Journal: Annals of Oncology (2020)
LOX-1は肥満マウスの腸間膜脂肪組織におけるMCP-1の過剰発現に必要である
Authors: Takanabe-Mori Rieko, Ono Koh, Sowa Naoya, Wada Hiromichi, Takaya Tomohide, Satoh Noriko, Shimatsu Akira, Fujita Masatoshi, Sawamura Tatsuya, Hasegawa Koji
Journal: Circulation (2010)
Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples
Authors: Flora Marzia Liotti, Giulia Menchinelli, Eleonora Lalle, Ivana Palucci, Simona Marchetti, Francesca Colavita, Marilena La Sorda, Giuseppe Sberna, Licia Bordi, Maurizio Sanguinetti, Paola Cattani, Maria Rosaria Capobianchi, Brunella Posteraro
Journal: Clinical Microbiology and Infection (2020)
Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors
Authors: Sudeep Banerjee, Abhishek Kumar, Nicole Lopez, Beiqun Zhao, Chih-Min Tang, Mayra Yebra, Hyunho Yoon, James D. Murphy, Jason K. Sicklick
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Gastrointestinal stromal tumor (GIST) is frequently driven by oncogenic<i>KIT</i>variations. Imatinib targeting of<i>KIT</i>marked a new era in GIST treatment and ushered in precision oncological treatment for all solid malignant neoplasms. However, studies on the molecular biological traits of GIST have found that tumors respond differentially to imatinib dosage based on the<i>KIT</i>exon with variation. Despite this knowledge, few patients undergo genetic testing at diagnosis, and empirical imatinib therapy remains routine. Barriers to genetic profiling include concerns about the cost and utility of testing. <h3>Objective</h3> To determine whether targeted gene testing (TGT) is a cost-effective diagnostic for patients with metastatic GIST from the US payer perspective. <h3>Design, Setting, and Participants</h3> This economic evaluation developed a Markov model to compare the cost-effectiveness of TGT and tailored first-line therapy compared with empirical imatinib therapy among patients with a new diagnosis of metastatic GIST. The main health outcome, quality-adjusted life years (QALYs), and costs were obtained from the literature, and transitional probabilities were modeled from disease progression and survival estimates from randomized clinical trials of patients with metastatic GIST. Data analyses were conducted October 2019 to January 2020. <h3>Exposure</h3> TGT and tailored first-line therapy. <h3>Main Outcomes and Measures</h3> The primary outcome was QALYs and cost. Cost-effectiveness was defined using an incremental cost-effectiveness ratio, with an incremental cost-effectiveness ratio less than $100 000/QALY considered cost-effective. One-way and probabilistic sensitivity analyses were conducted to assess model stability. <h3>Results</h3> Therapy directed by TGT was associated with an increase of 0.10 QALYs at a cost of $9513 compared with the empirical imatinib approach, leading to an incremental cost-effectiveness ratio of $92 100. These findings were sensitive to the costs of TGT, drugs, and health utility model inputs. Therapy directed by TGT remained cost-effective for genetic testing costs up to $3730. Probabilistic sensitivity analysis found that TGT-directed therapy was considered cost-effective 70% of the time. <h3>Conclusions and Relevance</h3> These findings suggest that using genetic testing to match treatment of<i>KIT</i>variations to imatinib dosing is a cost-effective approach compared with empirical imatinib.
881TiP A multi-centre, open-label phase II trial of the combination of VB10.16 and atezolizumab in patients with advanced or recurrent, non-resectable HPV16 positive cervical cancer
Authors: P. Hillemanns, J-F. Baurain, P. Blecharz, K. Lindemann, B. Nicolaisen, K. Schetne, A.B. Fredriksen, S. Torhaug
Journal: Annals of Oncology (2020)
435P Bevacizumab (bev) continuation with FOLFIRI or switch to aflibercept (afli) with FOLFIRI as second-line treatment (L2) after first line of FOLFOX-bev (L1) for metastatic colorectal cancer (mCRC): An AGEO multicenter study
Authors: C. Torregrosa, S. Pernot, A. Perret, V. Randrian, S. Racine Doat, B. Auberger, T. Godet, M. Jaffrelot, O. Dubreuil, A. Turpin, L-J. Palmieri, O. Bouche, T. Lecomte, D. Sefrioui, C. Locher, C. Neuzillet, E. Nassif, C. Lecaille, J. Taieb, E. Auclin
Journal: Annals of Oncology (2020)
1922P Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO-292)
Authors: L.J. Wirth, B. Robinson, V. Boni, D.S.W. Tan, C. McCoach, E. Massarelli, L.M. Hess, X. Huang, J.F. Kherani, E. Olek, V. Subbiah
Journal: Annals of Oncology (2020)
718P A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment
Authors: T.B. Powles, S. Oudard, V. Grünwald, E. Calvo, M.D. Michaelson, M. Burotto, B. Melichar, R. Tyagi, F. Hilmi, A. Gaur, Y. Hirschberg, D. Heng
Journal: Annals of Oncology (2020)
1445P CS1001, an anti-PD-L1 antibody, combined with standard of care (SOC) chemotherapy for first line (1L) advanced GC/GEJ and ESCC: Preliminary results from 2 phase Ib cohorts of CS1001-101 study
Authors: L. Shen, J. Li, Z. Miao, N. Xu, B. Liu, X. Li, Q. Zhang, Q. Gao, Y. Zhao, H. Pan, Z. Pei, W. Li, H. Xia, J. Wang, H. Dai, Q. Shi, J. Yang
Journal: Annals of Oncology (2020)
18F-FBPA PET in Sarcoidosis
Authors: Tadashi Watabe, Hiroaki Shimamoto, Sadahiro Naka, Takashi Kamiya, Shumei Murakami
Journal: Clinical Nuclear Medicine (2020)

Abstract A 68-year-old man with sarcoidosis showed high 18 F-FDG uptake in the mediastinal and hilar lymph nodes on 18 F-FDG PET, suggesting active inflammation. 18 F-fluoro-boronophenylalanine (FBPA) PET showed no significant uptake in the mediastinal and hilar lymph nodes, suggesting its cancer specificity as a substrate of l -type amino acid transporter 1. 18 F-fluoro-boronophenylalanine PET can be used for precise evaluation in oncology when the differentiation between inflammation and metastasis is inconclusive on 18 F-FDG PET.
9MO C-Myc regulates the cancer stem-cell phenotype differentially induced by the individual silencing of AKT isoforms in pancreatic adenocarcinoma
Authors: H. Arasanz, C. Hernández, M. Zuazo, L. Chocarro, A. Bocanegra-Gondan, G. Fernández-Hinojal, E. Blanco, E. Santamaría, J. Fernández-Irigoyen, E. Santamaría, C. Rodríguez, R. Vera, G. Kochan, D. Escors
Journal: Annals of Oncology (2020)
706MO Association between human papillomavirus (HPV) infection and outcome of perioperative nodal radiotherapy for penile carcinoma
Authors: A. Necchi, M. Bandini, J.S. Ross, Y. Zhu, Y. Ding-Wei, A. Ornellas, N. Watkin, B. Ayres, O. Hakenberg, A. Heidenreich, D. Raggi, P. Giannatempo, L. Marandino, J. Chipollini, M. Azizi, O. Brouwer, D. Grass, P. Johnstone, M. Albersen, P. Spiess
Journal: Annals of Oncology (2020)
1495P FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – Final results from the phase II RAMIRIS Study of the AIO
Authors: P.C. Thuss-Patience, S-E. Al-Batran, C. Pauligk, E. Goekkurt, T.J. Ettrich, F. Lordick, M. Stahl, P. Reichardt, M. Soekler, D. Pink, S. Probst, A. Hinke, T.O. Götze, S. Lorenzen
Journal: Annals of Oncology (2020)
1306P Platin pemetrexed with or without bevacizumab with upfront versus “at progression” brain radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis: A randomized phase III trial (Metal2 trial)
Authors: I. Monnet, A. Vergnenegre, G. Robinet, H. Berard, R. Lamy, L. Falchero, None S. vieillot, R. Schott, H. Lena, S. Chouabe, P. Thomas, R. Gervais, A-C. Madroszyk Flandin, S. Abdiche, A-M. Chiappa, L. Greillier, C. Decroisette, J.B. Auliac, C. Chouaid
Journal: Annals of Oncology (2020)
Disparities in COVID-19 Incidence, Hospitalizations, and Testing, by Area-Level Deprivation — Utah, March 3–July 9, 2020
Authors: Nathaniel M. Lewis, Mike Friedrichs, Shelly Wagstaff, Kylie Sage, Nathan LaCross, David Bui, Keegan McCaffrey, Bree Barbeau, Andrea George, Carolyn Rose, Sarah Willardson, Amy Carter, Christopher Smoot, Allyn Nakashima, Angela Dunn
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Coronavirus disease 2019 (COVID-19) has had a substantial impact on racial and ethnic minority populations and essential workers in the United States, but the role of geographic social and economic inequities (i.e., deprivation) in these disparities has not been examined (1,2). As of July 9, 2020, Utah had reported 27,356 confirmed COVID-19 cases. To better understand how area-level deprivation might reinforce ethnic, racial, and workplace-based COVID-19 inequities (3), the Utah Department of Health (UDOH) analyzed confirmed cases of infection with SARS-CoV-2 (the virus that causes COVID-19), COVID-19 hospitalizations, and SARS-CoV-2 testing rates in relation to deprivation as measured by Utah's Health Improvement Index (HII) (4). Age-weighted odds ratios (weighted ORs) were calculated by weighting rates for four age groups (≤24, 25-44, 45-64, and ≥65 years) to a 2000 U.S. Census age-standardized population. Odds of infection increased with level of deprivation and were two times greater in high-deprivation areas (weighted OR = 2.08; 95% confidence interval [CI] = 1.99-2.17) and three times greater (weighted OR = 3.11; 95% CI = 2.98-3.24) in very high-deprivation areas, compared with those in very low-deprivation areas. Odds of hospitalization and testing also increased with deprivation, but to a lesser extent. Local jurisdictions should use measures of deprivation and other social determinants of health to enhance transmission reduction strategies (e.g., increasing availability and accessibility of SARS-CoV-2 testing and distributing prevention guidance) to areas with greatest need. These strategies might include increasing availability and accessibility of SARS-CoV-2 testing, contact tracing, isolation options, preventive care, disease management, and prevention guidance to facilities (e.g., clinics, community centers, and businesses) in areas with high levels of deprivation.
LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial
Authors: Y. Vano, R.T. Elaidi, M. Bennamoun, C.M. Chevreau, D. Borchiellini, D. Pannier, D. Maillet, M. Gross-Goupil, C. Tournigand, B. Laguerre, P. Barthélémy, F. Joly, G. Gravis, S. Caruso, C-M. Sun, V. Verkarre, W-H. Fridman, J. Zucman-Rossi, C. Sautès-Fridman, S. Oudard
Journal: Annals of Oncology (2020)